Pulse Biosciences (PLSE) Shoots Up 16%

The significant rise in stock price follows a rights offering that was announced a week ago. Pulse announced its intention to issue”non-transferable subscription rights to its stockholders of record as of the Record Date to purchase up to $15,000,000 of units (the “Units,” and each, a “Unit”) at a subscription price per Unit equal to the lesser of (i) $3.72 per share, the closing price of the Common Stock on April 13, 2022 (the “Initial Price”) and (ii) the volume weighted average price of the Common Stock for the five-trading day period through and including the subscription expiration date (the “Alternate Price”)”

Despite the positive day for PLSE, the stock is still vastly far away from its 52-week high of $29.16.

Pulse Biosciences is housed in the PRISM Medical Devices Index, which, despite PLSE’s surge, has fallen 2.3% for the day.

About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit pulsebiosciences.com to learn more.

About the Author:

Stocks making the biggest moves premarket: American Eagle Outfitters, Five Below, MicroStrategy & more

Editor Prism MarketView

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt
ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida.